文献速递甲状腺疾病

Ca19.9阳性与倍增时间对无结构进展晚期甲状腺髓样癌的预后价值

Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors.
PubMed 文献 · Thyroid · 2021-01-07

本研究对107例晚期甲状腺髓样癌(aMTC)患者定期检测血清Ca19.9并计算倍增时间(DT),其中104例按RECIST进行影像学再分期。结果显示Ca19.9阳性及DT<6个月、<1年均与死亡显著相关(p<0.0001),但与RECIST定义的疾病进展无显著关联。

要点

  • Ca19.9阳性与aMTC患者死亡显著相关,但与RECIST疾病进展无关。
  • Ca19.9倍增时间<6个月和<1年均与死亡相关,与疾病进展无关。
  • 即使RECIST无进展证据,Ca19.9阳性或倍增时间短也应纳入是否启动系统治疗的决策。

核心结论

  • 血清Ca19.9阳性及倍增时间<6个月、<1个月是aMTC患者死亡的预后因素,但不是疾病进展的预后因素。
  • Ca19.9阳性及倍增时间<6个月、<1年应在决定是否启动系统治疗时予以考虑,即使RECIST无疾病进展证据。

研究设计与样本

  • 对107例晚期甲状腺髓样癌患者定期检测血清Ca19.9并计算倍增时间。
  • 104/107例患者进行影像学再分期,按RECIST评估疾病进展。

主要发现

  • 随访结束时107例中25例Ca19.9阳性,104例中30例出现疾病进展。
  • Ca19.9阳性与疾病进展无显著关联,与死亡显著关联(p<0.0001)。
  • Ca19.9倍增时间<6个月和<1年均与疾病进展无关,均与死亡相关(p<0.0001和p<0.0001)。
  • 3例Ca19.9倍增时间<6个月且RECIST无进展证据的患者分别于6、5、3个月后死于本病。

关键数值与推荐

  • Ca19.9阳性与死亡相关(p<0.0001)。
  • Ca19.9倍增时间<6个月与死亡相关(p<0.0001)。
  • Ca19.9倍增时间<1年与死亡相关(p<0.0001)。

临床怎么用

  • 对aMTC患者可定期检测血清Ca19.9并计算倍增时间以辅助预后评估。
  • 即使RECIST无结构进展证据,Ca19.9阳性或倍增时间<6个月、<1年时可考虑启动系统治疗的决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Serum Ca19.9 positivity is a prognostic factor for mortality in patients with advanced medullary thyroid cancer (aMTC), independently from calcitonin doubling time (DT). However, it is unknown whether aMTC patients who become positive for Ca19.9 also have progressive disease (PD) according to response evaluation criteria in solid tumors (RECIST) and whether Ca19.9 DT has a role in the management of aMTC patients. The aims of this study were to evaluate whether in aMTC, when serum Ca19.9 becomes positive, PD develops, and to determine the role of Ca19.9 DT in predicting mortality and PD. Patients and Methods: Serum Ca19.9 was periodically measured in 107 aMTC patients, and the DTs were calculated. Restaging of the disease was radiologically performed in 104 of 107 patients and PD was evaluated according to RECIST. Results: At the end of follow-up, 25 of 107 patients were Ca19.9 positive and PD was identified in 30 of 104 patients. No significant association was found between Ca19.9 positivity and PD, while there was a significant association between Ca19.9 positivity and mortality (p < 0.0001). Ca19.9 DTs <6 months and <1 year were not associated with PD but were associated with mortality (p < 0.0001 and p < 0.0001, respectively). In particular, 3 patients who had a Ca19.9 DT <6 months with no evidence of PD according to RECIST died of their disease after 6, 5, and 3 months, respectively. Conclusions: Serum Ca19.9 positivity and DTs <6 months and <1 year are prognostic factors for mortality but not for PD. Serum Ca19.9 positivity and DTs <6 months and <1 year should be considered in the decision-making process of whether to initiate systemic therapy even if there is no evidence of PD according to RECIST.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lorusso L, Romei C, Piaggi P, et al. Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors. Thyroid. 2021. PMID: 33234054. doi:10.1089/thy.2020.0060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。